Therapeutic Efficacy of HPβ‐CD‐Angiotensin‐(1‐7) Oral Formulation in Muscle Injury Recovery in Rat
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70851 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Nádia Lúcia Totou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Biological Sciences Research Center-Postgraduate Program in Biological Sciences, Federal University of Ouro Preto, Ouro Preto, Brazil. Hauptthemen laut MEDLINE: Muscle, Skeletal, Angiotensin I, Peptide Fragments. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Nanobiofar Technology Institute (INCT-Nanobiofar), Minas Gerais State Research Foundation (FAPEMIG), Personal resources of the researchers.
Abstract (Originalsprache)
To evaluate the therapeutic effect of oral treatment with HPβ‐CD‐angiotensin‐(1‐7) (Ang‐(1‐7)) on muscle recovery after laceration injury. Wistar rats were divided into four groups: Control ( n = 10); HPβ‐CD‐Ang‐(1‐7) ( n = 10); muscle injury + HPβ‐CD (MI + Placebo) ( n = 24); and muscle injury + HPβ‐CD‐Ang‐(1‐7) (MI + Ang‐(1‐7)) ( n = 24). After 7–21 days of treatment, physical performance, histological features and the expression of pro‐ and anti‐fibrotic genes were evaluated. The MI + Ang‐(1‐7) group showed improved control of the inflammatory phase and reduced deposition of collagen types I and III compared to MI + Placebo. CTGF gene expression analysis revealed lower levels of pro‐fibrotic markers and higher expression of proteins involved in blocking fibrotic pathways. In treadmill tests, MI + Ang‐(1‐7) animals also showed superior physical performance at all evaluated time points. Oral treatment with Ang‐(1‐7) is effective in promoting recovery from muscle injuries, particularly fibrotic lesions, while preserving muscle function and enhancing physical performance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biological Sciences Research Center-Postgraduate Program in Biological Sciences, Federal University of Ouro Preto, Ouro Preto, Brazil.
- School of Physical Education, Federal University of Ouro Preto, Ouro Preto, Brazil.
- Department of Physiology and Biophysics, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil.
ORCID-Profile: Emerson Cruz de Oliveira
Förderung
- National Nanobiofar Technology Institute (INCT-Nanobiofar)
- Minas Gerais State Research Foundation (FAPEMIG)
- Personal resources of the researchers
- Higher Education Personnel Improvement Coordination (CAPES)
- National Council for Scientific and Technological Development (CNPq)
- Federal University of Ouro Preto using resources from the Pro-Rectorate of Research, Graduate Studies and Innovation (PROPPI)
- Minas Gerais State Research Foudation (FAPEMIG)
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais
Zitieren
APA
Totou, N. L., Rocha, A. M. S., de Moura, S. S., Pereira, C. H., Coelho, F. S., Dophine, D. D., Coelho, D. B., de Oliveira, E. C., Dos Santos, R. A. S., Becker, L. K., & de Lima, W. G. (2025). Therapeutic Efficacy of HPβ‐CD‐Angiotensin‐(1‐7) Oral Formulation in Muscle Injury Recovery in Rat. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70851
Vancouver
Totou NL, Rocha AMS, de Moura SS, Pereira CH, Coelho FS, Dophine DD, et al. Therapeutic Efficacy of HPβ‐CD‐Angiotensin‐(1‐7) Oral Formulation in Muscle Injury Recovery in Rat. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70851
BibTeX
@article{Totou2025,
author = {Totou, Nádia Lúcia and Rocha, Ana Maria Sampaio and de Moura, Samara Silva and Pereira, César Henrique and Coelho, Fabricio Sampaio and Dophine, Douglas Daniel and Coelho, Daniel Barbosa and de Oliveira, Emerson Cruz and Dos Santos, Robson Augusto Souza and Becker, Lenice Kappes and de Lima, Wanderson Geraldo},
title = {Therapeutic Efficacy of HPβ‐CD‐Angiotensin‐(1‐7) Oral Formulation in Muscle Injury Recovery in Rat},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70851}
}
EUVIMED